Personal Genome Diagnostics Inc.

Sell-side

Exclusive Financial Advisor, February 2022

Sale to Labcorp (NYSE: LH)

Since its founding in 2010, PGDx has empowered the fight against cancer by unlocking actionable information from the genome to drive biomarker informed treatment plans. The PGDx elio™ portfolio of tissue-based and liquid biopsy comprehensive genomic solutions enable personalized care for all patients by bringing precision oncology testing to where they are. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.

More Like This

May 2022

Sale of GeneDx, Inc., a Subsidiary of OPKO Health, Inc. (NASDAQ: OPK) to Sema4 Holdings Corp. (SMFR)

Financial Advisor

View Details
Apr 2022
Proven Behavior Solutions Logo

Strategic Investment From Health Enterprise Partners

Exclusive Financial Advisor

View Details
Jul 2021

Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD acquired by BioNTech

Financial Advisor

View Details